Paras Biopharmaceuticals Finland Oy

Paras Biopharmaceuticals Finland Oy is an up-and-coming biopharmaceutical technology development company which has successfully developed the Diabrid Platform Technology proprietary for the high level expression of biosimilars in specially designed genetically stable clones.

Paras Biopharmaceuticals Finland Oy is a joint venture started in 2009 by a team of scientists and technologists who have extensive research experience and skills in the development of biologics and biosimilar technologies. Paras Biopharmaceuticals Finland Oy engages in the development and improvement of biological processes and expression of recombinant proteins in E. Coli and Pichia pastoris.